CDX
RPMI 8226
Tumor indication
Lymphoid
Tumor subtype
Multiple Myeloma
Description
RPMI 8226 (Multiple Myeloma CDX Model)
The RPMI 8226 line was derived from the peripheral blood of a patient with multiple myeloma. It represents malignant plasma cells and secretes immunoglobulin. RPMI 8226 is widely used in preclinical drug development for myeloma. Its reproducibility makes it valuable for translational hematology research.
Key Features:
- Derived from multiple myeloma blood sample.
- Produces immunoglobulin light chains.
- Plasma cell phenotype.
- Tumorigenic in xenografts.
Applications:
RPMI 8226 supports evaluation of novel myeloma therapies and biomarkers. Researchers use it in resistance mechanism and immunotherapy studies. It is also applied in drug screening programs for hematology. Its reproducibility ensures reliability in translational research.
Details
- Tumor indication
- Lymphoid
- Tumor subtype
- Multiple Myeloma
- Organism
- Human
- Mouse sex
- Female
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.